The U.S. health regulator has declined to approve Rocket Pharmaceuticals’ gene therapy to treat a rare and severe pediatric disorder that causes the immune system to malfunction.
ARS Pharmaceuticals said the European Medicines Agency (EMA) has recommended the approval of its needle-free emergency treatment, EURneffy, for allergic reactions.
The companies have launched their Alzheimer’s treatment Leqembi in China, the third country after the United States and Japan.
The company announced that a Phase III trial of its hypertension and chronic kidney disease candidate failed to hit the primary endpoint, with the Danish drugmaker deciding to discontinue the study and incur an impairment loss of DKK 5.7 billion ($818.9 million) in the second quarter of 2024.
The sun has set on the 71st Cannes Lions International Festival of Creativity, and much has been written regarding AI in the advertising industry, the future of PR and celebrities du jour, including Chrissy Teigen, John Legend, José Andrés, and more! Amid the fanfare, pharma continues to loom large and several key learnings came to light relevant to the industry.
Today the U.S. Supreme Court on Thursday blocked OxyContin maker Purdue Pharma’s bankruptcy settlement that would have shielded its wealthy Sackler family owners from lawsuits over their role in the nation’s deadly opioid epidemic.